Completed PHASE1 INTERVENTIONAL 2-arm NCT00931931

HSV1716 in Patients With Non-Central Nervous System (Non-CNS) Solid Tumors

A Phase I Dose Escalation Study of Intratumoral or Intravenous Herpes Simplex Virus-1 Mutant HSV1716 in Patients With Refractory Non-Central Nervous System (Non-CNS) Solid Tumors

Sponsor: Timothy Cripe

Conditions Clival Chordoma Ewing Sarcoma Malignant Peripheral Nerve Sheath Tumor Neuroblastoma Non-CNS Solid Tumors Osteosarcoma Rhabdomyosarcoma Soft Tissue Sarcoma Wilms Tumor

Interventions HSV1716

Updated 7 times since 2017 Last updated: Mar 19, 2018 Started: Mar 31, 2010 Primary completion: Mar 19, 2018 Completion: Mar 19, 2018

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT00931931, this PHASE1 trial focuses on Clival Chordoma and Ewing Sarcoma and remains completed. Sponsored by Timothy Cripe, it has been updated 7 times since 2010, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Status Flow

Change History

7 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE1
Jul 2024 — Sep 2024 [monthly]

Completed PHASE1
Jan 2021 — Jul 2024 [monthly]

Completed PHASE1
Jun 2018 — Jan 2021 [monthly]

Completed PHASE1
Apr 2018 — Jun 2018 [monthly]

Completed PHASE1

Status: Recruiting → Completed

▶ Show 2 earlier versions

Feb 2017 — Apr 2018 [monthly]

Recruiting PHASE1
Jan 2017 — Feb 2017 [monthly]

Recruiting PHASE1

First recorded

Mar 2010

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Timothy Cripe

Data source: Nationwide Children's Hospital

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Columbus, United States